Evinacumab is an ANGPTL3 inhibitor that has been approved by the FDA for the treatment of adult and pediatric patients aged 12 years and older with homozygous FH, refractory hypercholesterolemia, and severe hypertriglyceridemia [65]. Here, ANGPTL3 is linked to familial hyperaldosteronism.